We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The European Investment Bank is making available up to $113 million in financing for BioNTech’s BNT162, a messenger RNA-based vaccine, and the scaling up of manufacturing capacity for it in Europe. Read More
Fujifilm said it plans to invest $928 million to double production capacity at its biologics manufacturing facility in Denmark to supply bulk drug substances for future COVID-19 therapies and other products. Read More
Partly in response to the COVID-19 pandemic, HHS is partnering with a Boston-based drugmaker to create a domestic supply chain that doesn’t rely on foreign sources for active pharmaceutical ingredients. Read More
Oxford Biomedica has signed a five-year collaboration agreement with the Vaccines Manufacturing and Innovation Center (VMIC) to manufacture viral vector-based vaccines. Read More
The funding also includes a delivery of 10 million doses this year that can be used in phase 2/3 clinical trials or under Emergency Use Authorization. Read More
Inovio Pharmaceuticals has sued its primary vaccine manufacturer VGXI for alleged breach of contract over production of Inovio’s COVID-19 vaccine candidate. Read More